Histone Deacetylase 8 – Pipeline Review, H2 2018 – ResearchByMarkets

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) – Pipeline Review, H2 2018

According to the recently published report ‘Histone Deacetylase 8 – Pipeline Review, H2 2018’; Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. 

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) – Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. 

The report ‘Histone Deacetylase 8 – Pipeline Review, H2 2018’ outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, IND/CTA Filed and Preclinical stages are 1, 1 and 4 respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Colon Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Adenoid Cystic Carcinoma (ACC), Alzheimer’s Disease, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Bone Disorders, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Mycosis Fungoides, Natural Killer Cell Lymphomas, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Renal Cell Carcinoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/45718

Scope

– The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
– The report reviews Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
– The report reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects 
– The report assesses Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
– The report summarizes all the dormant and discontinued pipeline projects 
– The report reviews latest news and deals related to Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
– Identify and understand the targeted therapy areas and indications for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies 
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) development landscape 
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Buy this report via Credit Card/Paypal or Wire Transfer:
https://www.researchbymarkets.com/paynow/45718

Companies Mentioned: 
AlfaSigma SpA
Chipscreen Biosciences Ltd
HitGen LTD
NatureWise Biotech & Medicals Corp
Zhejiang Hisun Pharmaceutical Co Ltd

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://ww.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchbymarkets/
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.